*Unless otherwise defined herein, capitalised terms in this announcement shall have the same meanings as those defined in the prospectus dated 12 September 2019 (the "**Prospectus**") issued by Shanghai Henlius Biotech, Inc. (the "**Company**").*

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and Hong Kong Securities Clearing Company Limited ("**HKSCC**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the



The C m an i ini iall ffe ing 64,695,400 H Sha e (bjec he O e -all men O i n) nde he Gl bal Offe ing, hich c n i f 6,469,600 H ng K ng Offe Sha e (bjec eall ca i n) and 58,225,800 In e na i nal Offe Sha e (bjec eall ca i n and he O e -all men O i n), e e en ing a ima el 10% and 90% f he al m mbe f Offe Sha e ini iall a ailable nde he Gl bal Offe ing, e ec i el . Of he 58,225,800 Offe Sha e ini iall being ffe ed nde he In e na i nal Offe ing, 8,372,000 Offe Sha e (e e en ing a ima el 14.38% and 12.94% f he Offe Sha e ini iall being ffe ed nde he In e na i nal Offe ing and he Gl bal Offe ing, e ec i el) ill be ffe ed he Q alif ing F n In e na i nal Sha eh lde and he Q alif ing F n Pha ma H Sha eh lde a an A ed En i lemen b a f he Pe fe en ial Offe ing. The all ca i n f he Offe Sha e be een he In e na i nal Offe ing and he H ng K ng P blic Offe ing, in each ca e, ill be bjec eall ca i n n he ba i a de cibed in he ec i n headed S c e f he Gl bal Offe ing in he P ec . The Re e ed Sha e a e n bjec ch eall ca i n. In acc dance i h G idance Le e HKE -GL91-18 i ed b he S ck E change, if ch eall ca i n i d ne he han a an P ac ice N e 18 f he Li ing R le , he ma im m al m mbe f Offe Sha e ha ma be all ca ed he H ng K ng P blic Offe ing f ll ing ch eall ca i n hall be n m e han ime he m mbe f H ng K ng Offe Sha e ini iall a ailable nde he H ng K ng P blic Offe ing (i.e. 12,939,200 Offe Sha e).

In c nnec i n i h he Gl bal Offe ing, he C m an i e ec ed gan he O e -all men O i n he In e na i nal Unde i e , hich ill be e e ci able b he J in Re e en a i e (f hem el e and n behalf f he In e na i nal Unde i e) a an ime f m he Li ing Da e he 30 h da af e he la da f he l dging f a lica i n nde he H ng K ng P blic Offe ing (being Th da , 17 Oc be 2019). P an he O e -all men O i n, he C m an ma be e i ed all and i e 9,704,300 addi i nal Offe Sha e , e e en ing a ima el 15% f he Offe Sha e ini iall a ailable nde he Gl bal Offe ing, a he Offe P ice, c e e -all ca i n in he In e na i nal Offe ing, if an . In he e en he O e -all men O i n i e e ci ed, he m mbe f Re e ed Sha e ill n change.

S bjec he gan ing f he a al f he li ing f, and e mi i n deal in, he H Sha e n he S ck E change and c m liance i h he ck admi i n e i emen f HKSCC, he H Sha e ill be acce ed a eligible ec i ie b HKSCC f de i , clea ance and e lemen in CCASS i h effec f m he da e f c mmencemen f dealing in he H Sha e n he S ck E change, ch he da e a ma be de e mined b HKSCC. Se lemen f an ac i n be een a ici an f he S ck E change i e i ed ake lace in CCASS n he ec nd b ine da af e an ading da . All ac i i ie nde CCASS a e bjec he Gene al R le f CCASS and he CCASS O e a i nal P ced e in effec f m ime ime. All nece a a angemen ha e been made enable he H Sha e be admi ed in CCASS. In e h ld eek he ad ice f hei ckb ke he fe i nal ad i e f de ail f he e lemen a angemen a ch a angemen ma affec hei igh and in e e .

The Offer Price will not be more than HK$57.80 per Offer Share and is expected to be not less than HK$49.60 per Offer Share unless otherwise announced as further explained in the section headed Structure of the Global Offering in the Prospectus. Applications for the Hong Kong Offer Shares and the Reserved Shares are required, in addition, to be paid brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%, subject to refund if the Offer Price as finally determined is less than HK$57.80 per Offer Share.

Important

The C m an ill be el ing n Sec i n 9A f he C m anie (E em i n f C m anie and P ec e f m C m liance i h P i i n) N ice (Cha e 32L f he La f H ng K ng) and ill be i ing (i) he **WHITE** and **YELLOW** A lica i n F m i h hem being acc m anied b a in ed P ec ; and (ii) he **ORANGE** A lica i n F m he ele an Q alif ing F n In e na i nal Sha eh lde and he **BLUE** A lica i n F m he ele an Q alif ing F n Pha ma H Sha eh lde i h hem being acc m anied b a in ed P ec , nle he ele an Q alif ing F n In e na i nal Sha eh lde he ele an Q alif ing F n Pha ma H Sha eh lde (a he ca e ma be) ha e elec ed ece i e c a e c mm nica i n in in ed f m nde he c a e c mm nica i n lic f F n In e na i nal F n Pha ma (a he ca e ma be), ha e n been a ked elec he mean f ecei ing he c a e c mm nica i n f F n In e na i nal F n Pha ma (a he ca e ma be), in hich ca e he in ed P ec ill be de a ched hem e a a el . The c n en f he in ed P ec a e iden ical he elec nic Theb a eimch be(P ec he)-5e(P e3.7(a)-28bn

New Territories	Me r Ci Br anch	Sh 209, Le el 2, Me r Ci Pha e 1, T e ng K an O, Ne Te i ie
	Ma On Shan Plaza Br anch	Sh 2103, Le el 2, Ma On Shan Plaza, Sai Sha R ad, Ma On Shan, Ne Te i ie

CMB Wing Lung Bank Limited

District	**Branch Name**	**Address**
Hong Kong Island	Head Office	45 De V e R ad Cen ral
	Kenned T n Br anch	28 Ca chick S ee
Kowloon	M ngk k Br anch	B/F CMB Wing L ng Bank Cen e, 636 Na han R ad
	T im Sha T i Br anch	4 Ca nar n R ad
New Territories	T en Wan Br anch	251 Sha T i R ad

2. an f he f ll ing ffice f he bel J in Gl bal C rdina r :

China International Capital Corporation Hong Kong Securities Limited
29 h Fl r, One In e na i nal Finance Cen e
1 Ha b r Vie S ee
Cen ral
H ng K ng

Merrill Lynch (Asia Pacific) Limited
Le el 55 Che ng K ng Cen e
2 Q een' R ad Cen ral
Cen ral
H ng K ng

BOCI Asia Limited
26 h Fl r, Bank f China T e
1 Ga den R ad
Cen ral
H ng K ng

UBS AG Hong Kong Branch
52/F, T In e na i nal Finance Cen e
8 Finance S ee
Cen ral
H ng K ng

CMB International Capital Limited
45/F, Cham i n T v e
3 Ga den R ad
Cen al
H ng K ng

Fosun Hani Securities Limited
Si i e 2101-2105 21/F Cham i n T v e
3 Ga den R ad
Cen al
H ng K ng

3. he De i C n e f HKSCC a 1/F, One & T E change S a e, 8 C nna gh Place, Cen al, H ng K ng.

Details of where printed Prospectuses may be obtained will be displayed prominently at every designated branch of receiving banks where WHITE Application Forms are distributed.

D ing n mal b ine h f m 9:00 a.m. n Th da , 12 Se embe 2019 n il 12:00 n n n Tu e da , 17 Se embe 2019, a lea hee c ie f he in ed P ec v ill be a ailable f in ec i n a e e l ca i n, he e he **WHITE** and **YELLOW** A lica i n F m a e di ib ed a e in he ec i n headed H v A l f H ng K ng Offe Sha e and Re e ed Sha e in he P ec .

C ie f he **WHITE** A lica i n F m ma be b ained d ing n mal b ine h f m 9:00 a.m. n Th da , 12 Se embe 2019 n il 12:00 n n n Tu e da , 17 Se embe 2019 a he f ll v ing l ca i n :

1. an f he f ll v ing b anche f he ecei ing bank f he H ng K ng P blic Offe ing:

Bank of China (Hong Kong) Limited

District	Branch Name	Address
Hong Kong Island	De V e R ad We Banch	111-119 De V e R ad We , H ng K ng
	Chai Wan Banch	Bl ck B, Wal n E a e, 341-343 Chai Wan R ad, Chai Wan, H ng K ng

Kowloon	Telford Plaza Branch	Shop Unit P2-P7, Telford Plaza, No.33 Wai Yip Street, Kwun Tong, Kowloon
	Olympian City Branch	Shop 133, 1/F, Olympian City 2, 18 Hoi Ting Road, Kowloon
New Territories	Metro City Branch	Shop 209, Level 2, Metro City Phase 1, Tseung Kwan O, New Territories
	Ma On Shan Plaza Branch	Shop 2103, Level 2, Ma On Shan Plaza, Sai Sha Road, Ma On Shan, New Territories

CMB Wing Lung Bank Limited

District	**Branch Name**	**Address**
Hong Kong Island	Head Office	45 Des Voeux Road Central
	Kennedy Town Branch	28 Catchick Street
Kowloon	Mongkok Branch	B/F CMB Wing Lung Bank Centre, 636 Nathan Road
	Tim Sha Tsui Branch	4 Carnarvon Road
New Territories	Tsuen Wan Branch	251 Sha Tsui Road

2. and the following offices of the below Joint Global Coordinators:

China International Capital Corporation Hong Kong Securities Limited
29th Floor, One International Finance Centre
1 Harbour View Street
Central, Hong Kong

Merrill Lynch (Asia Pacific) Limited
Level 55 Cheung Kong Center
2 Queen's Road Central
Central
Hong Kong

BOCI Asia Limited
26th Floor, Bank of China Tower
1 Garden Road
Central
Hong Kong

UBS AG Hong Kong Branch
52/F, T In e na i nal Finance Cen e
8 Finance S ee
Cen al
H ng K ng

CMB International Capital Limited
4.Qance S ee 8Cen al
H 92TD083.Qance82.9(K ng)TJ/F41Tf0-2.4792TD625.QanceF nee Cen al
H ng K ng

Qualifying Foreign Investor Shareholders who require replacement **ORANGE** Application Form for Qualifying Foreign Pharma H Shareholders who require replacement **BLUE** Application Form should contact Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for such forms during normal business hours by telephone enquiry line 2862 8555. Printed copies of the Prospectus can be collected from the branches of the designated receiving bank or the office of the Joint Global Coordinators as aforesaid above.

The C m an e ec announce he final Offe P ice, he le el f indica i n f in e e in he In e na i nal Offe ing, he le el f a lica i n in he H ng K ng P blic Offe ing and he P efe en ial Offe ing and he ba i f all ca i n f he H ng K ng Offe Sha e and he Re e ed Sha e n Tue da , 24 Se embe 2019 (i) in S h China M ning P (in Engli h); (ii) in H ng K ng Ec n mic Time (in Chine e); (iii) n he eb i e a **www.henlius.com**; and (i) n he eb i e f he S ck E change a **www.hkexnews.hk**.

The e l f all ca i n and he H ng K ng iden i ca d/ a /H ng K ng b ine egi a i n mbe f cce fi l a lican nde he H ng K ng P blic Offe ing and he P efe en ial Offe ing ill be made a ailable a he ime and da e and in a manne de c ibed in he ec i n headed H A l f H ng K ng Offe Sha e and Re e ed Sha e E. P blica i n f Re l in he P ec .

The C m an ill n i e em a d c men f i le eceip f a lica i n fee eceiv ed. Sha e ce ifica e ill nl bec me alid ce ifica e f i le a 8:00 a.m. n Wedne da , 25 Se embe 2019 ided ha he Gl bal Offe ing ha bec me nc ndi i nal in all e ec and he igh f e mina i n de c ibed in he ec i n headed Unde ing ha n been e e ci ed.

Dealing in he H Sha e n he S ck E change a e e ec ed c mmence a 9:00 a.m. n Wedne da , 25 Se embe 2019. The H Sha e ill be aded in b a d l f 100 H Sha e each nde he C m an ' ck c de 2696.

By order of the Board of Directors
Shanghai Henlius Biotech Inc.
Qiyu Chen
Chairman

Shanghai, 12 September 2019

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Scott Shi-Kau Liu as the executive Director, Mr. Qiyu Chen as the chairman and non-executive Director, Mr. Yifang Wu, Mr. Jiemin Fu, Mr. Aimin Hui and Ms. Xiaohui Guan as the non-executive Directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Mr. Ruilin Song as the independent non-executive Directors.

Please also refer to the published version of this announcement in the South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese).